4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom.

The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease.

It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis.

In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines.

The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.